- Home
- MRM vs SNTI Comparison
MRM vs SNTI Comparison
Compare MRM & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- SNTI
- Stock Information
- Founded
- MRM 2000
- SNTI 2016
- Country
- MRM Japan
- SNTI United States
- Employees
- MRM N/A
- SNTI N/A
- Industry
- MRM Other Consumer Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- SNTI Health Care
- Exchange
- MRM Nasdaq
- SNTI Nasdaq
- Market Cap
- MRM 5.9M
- SNTI 85.3M
- IPO Year
- MRM 2020
- SNTI N/A
- Fundamental
- Price
- MRM N/A
- SNTI $2.26
- Analyst Decision
- MRM
- SNTI Strong Buy
- Analyst Count
- MRM 0
- SNTI 2
- Target Price
- MRM N/A
- SNTI $8.50
- AVG Volume (30 Days)
- MRM 30.7K
- SNTI 385.8K
- Earning Date
- MRM 05-20-2025
- SNTI 08-12-2025
- Dividend Yield
- MRM N/A
- SNTI N/A
- EPS Growth
- MRM 27.65
- SNTI N/A
- EPS
- MRM 0.18
- SNTI N/A
- Revenue
- MRM $52,786,758.00
- SNTI N/A
- Revenue This Year
- MRM N/A
- SNTI N/A
- Revenue Next Year
- MRM N/A
- SNTI $150.00
- P/E Ratio
- MRM $7.77
- SNTI N/A
- Revenue Growth
- MRM 21.55
- SNTI N/A
- 52 Week Low
- MRM $0.34
- SNTI $1.52
- 52 Week High
- MRM $8.39
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- MRM 50.69
- SNTI 37.88
- Support Level
- MRM $1.32
- SNTI $2.05
- Resistance Level
- MRM $1.50
- SNTI $2.35
- Average True Range (ATR)
- MRM 0.09
- SNTI 0.30
- MACD
- MRM -0.03
- SNTI 0.00
- Stochastic Oscillator
- MRM 27.69
- SNTI 20.00
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.